NASDAQ:CRNX

Crinetics Pharmaceuticals Stock Forecast, Price & News

$18.94
+1.96 (+11.54 %)
(As of 06/14/2021 12:00 AM ET)
Add
Compare
Today's Range
$17.05
$18.97
50-Day Range
$15.90
$18.94
52-Week Range
$11.61
$23.70
Volume174,867 shs
Average Volume135,208 shs
Market Capitalization$712.01 million
P/E RatioN/A
Dividend YieldN/A
Beta1.26
30 days | 90 days | 365 days | Advanced Chart
Receive CRNX News and Ratings via Email

Sign-up to receive the latest news and ratings for Crinetics Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Crinetics Pharmaceuticals logo

About Crinetics Pharmaceuticals

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 biased agonist that has completed phase II clinical trial for the treatment of acromegaly, as well as completed phase 1 clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist to treat congenital hyperinsulinism, which is in phase 1 clinical trial; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase 1 clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was founded in 2008 and is headquartered in San Diego, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.81 out of 5 stars

Medical Sector

191st out of 2,100 stocks

Pharmaceutical Preparations Industry

89th out of 831 stocks

Analyst Opinion: 3.4Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Crinetics Pharmaceuticals (NASDAQ:CRNX) Frequently Asked Questions

Is Crinetics Pharmaceuticals a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Crinetics Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Crinetics Pharmaceuticals stock.
View analyst ratings for Crinetics Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Crinetics Pharmaceuticals?

Wall Street analysts have given Crinetics Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Crinetics Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Crinetics Pharmaceuticals' next earnings date?

Crinetics Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Friday, August 6th 2021.
View our earnings forecast for Crinetics Pharmaceuticals
.

How were Crinetics Pharmaceuticals' earnings last quarter?

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) issued its quarterly earnings data on Thursday, May, 6th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.66) by $0.03.
View Crinetics Pharmaceuticals' earnings history
.

How has Crinetics Pharmaceuticals' stock price been impacted by Coronavirus (COVID-19)?

Crinetics Pharmaceuticals' stock was trading at $15.50 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CRNX shares have increased by 22.2% and is now trading at $18.94.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for CRNX?

5 analysts have issued 12 month price targets for Crinetics Pharmaceuticals' stock. Their forecasts range from $33.00 to $42.00. On average, they anticipate Crinetics Pharmaceuticals' stock price to reach $39.00 in the next twelve months. This suggests a possible upside of 105.9% from the stock's current price.
View analysts' price targets for Crinetics Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Crinetics Pharmaceuticals' key executives?

Crinetics Pharmaceuticals' management team includes the following people:
  • Dr. R. Scott Struthers, Founder, Pres, CEO & Director (Age 59, Pay $715.39k)
  • Mr. Marc J. C. Wilson, CFO & Sec. (Age 42, Pay $450k)
  • Dr. Alan S. Krasner, Chief Medical Officer (Age 58, Pay $571.97k)
  • Dr. Yun-Fei Zhu, Founder & VP of Chemistry (Age 58)
  • Dr. Stephen F. Betz, Co-Founder & VP of Biology (Age 55)
  • Ms. Adriana Cabre, VP of HR
  • Dr. Ajay Madan DABT, Ph.D., D.A.B.T., Chief Devel. Officer (Age 53)
  • Mr. Peter Trainer BSc, MBChB, M.D., FRCP, VP of Clinical Endocrinology
  • Ms. Gina Ford M.B.A., R.Ph., RPh, VP of Corp. Strategy & Commercial Planning

What is R. Scott Struthers, Ph.D.'s approval rating as Crinetics Pharmaceuticals' CEO?

2 employees have rated Crinetics Pharmaceuticals CEO R. Scott Struthers, Ph.D. on Glassdoor.com. R. Scott Struthers, Ph.D. has an approval rating of 100% among Crinetics Pharmaceuticals' employees. This puts R. Scott Struthers, Ph.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Crinetics Pharmaceuticals' key competitors?

What other stocks do shareholders of Crinetics Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Crinetics Pharmaceuticals investors own include SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), G1 Therapeutics (GTHX), Kura Oncology (KURA), Otonomy (OTIC), Selecta Biosciences (SELB), TG Therapeutics (TGTX), Arbutus Biopharma (ABUS) and Applied Genetic Technologies (AGTC).

When did Crinetics Pharmaceuticals IPO?

(CRNX) raised $80 million in an IPO on Wednesday, July 18th 2018. The company issued 5,000,000 shares at $15.00-$17.00 per share. J.P. Morgan, Leerink Partners and Piper Jaffray acted as the underwriters for the IPO.

What is Crinetics Pharmaceuticals' stock symbol?

Crinetics Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRNX."

Who are Crinetics Pharmaceuticals' major shareholders?

Crinetics Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Vivo Capital LLC (5.89%), BlackRock Inc. (5.76%), Point72 Asset Management L.P. (3.39%), Geode Capital Management LLC (1.00%), Northern Trust Corp (0.79%) and Bank of New York Mellon Corp (0.76%). Company insiders that own Crinetics Pharmaceuticals stock include Matthew K Fust, Perceptive Advisors Llc, Richard Scott Struthers, Ventures Iv LP 5Am and Vivo Capital Viii, Llc.
View institutional ownership trends for Crinetics Pharmaceuticals
.

Which institutional investors are selling Crinetics Pharmaceuticals stock?

CRNX stock was sold by a variety of institutional investors in the last quarter, including Vivo Capital LLC, Price T Rowe Associates Inc. MD, Northern Trust Corp, PDT Partners LLC, JPMorgan Chase & Co., Credit Suisse AG, Nuveen Asset Management LLC, and Citigroup Inc..
View insider buying and selling activity for Crinetics Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying Crinetics Pharmaceuticals stock?

CRNX stock was bought by a variety of institutional investors in the last quarter, including Sphera Funds Management LTD., Opaleye Management Inc., Geode Capital Management LLC, BlackRock Inc., Point72 Asset Management L.P., Dimensional Fund Advisors LP, Victory Capital Management Inc., and Morgan Stanley. Company insiders that have bought Crinetics Pharmaceuticals stock in the last two years include Perceptive Advisors Llc, and Richard Scott Struthers.
View insider buying and selling activity for Crinetics Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Crinetics Pharmaceuticals?

Shares of CRNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Crinetics Pharmaceuticals' stock price today?

One share of CRNX stock can currently be purchased for approximately $18.94.

How much money does Crinetics Pharmaceuticals make?

Crinetics Pharmaceuticals has a market capitalization of $712.01 million and generates $70,000.00 in revenue each year. The company earns $-73,810,000.00 in net income (profit) each year or ($2.42) on an earnings per share basis.

How many employees does Crinetics Pharmaceuticals have?

Crinetics Pharmaceuticals employs 93 workers across the globe.

What is Crinetics Pharmaceuticals' official website?

The official website for Crinetics Pharmaceuticals is www.crinetics.com.

Where are Crinetics Pharmaceuticals' headquarters?

Crinetics Pharmaceuticals is headquartered at 10222 Barnes Canyon Road Building #2, San Diego CA, 92121.

How can I contact Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals' mailing address is 10222 Barnes Canyon Road Building #2, San Diego CA, 92121. The company can be reached via phone at 858-450-6464 or via email at [email protected]


This page was last updated on 6/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.